Popular Stories

Biotechnology

Accuray Incorporated at a Key Inflection Point

Accuray Inc (NASDAQ: ARAY), a Company developing robotic stereotactic radiosurgery and stereotactic body radiation therapy system, specifically the CyberKnife System, announced the data from a prospective study which demonstrates the efficacy and safety of its stereotactic body radiation therapy (SBRT), administered using the CyberKnife system....

Greenlane Holdings – In the fast lane with expanding global footprint

GreenLane Holdings Inc (NASDAQ: GNLN), a Company dealing in wholesale and retail distribution of consumption accessories and vaporization products, announced a comprehensive distribution agreement with Advanced Vapor Devices (AVD), a manufacturer of vaporizer cartridges and batteries. The agreement will cover the entire range of AVD...

ChromaDex Seeking to Redefine Its “Anti-Aging” Pill Persona

ChromaDex (NASDAQ: CDXC), a nutraceutical Company focussed on improving the way people age, announced the launch of a “first-of-its-kind” Phase 1 clinical study to test the safety, efficacy and potential of branded nicotinamide riboside (NR), Niagen, in improving the effects of exercise therapy in older...

Pulmatrix Soars on News of Licensing Agreement with Johnson & Johnson

Pulmatrix Inc (NASDAQ: PULM), a Clinical Stage Biopharmaceutical Company developing inhaled therapies for the treatment of pulmonary diseases, announced the signing of a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson (NYSE: JNJ), enabling the initiative to access the Company’s...

Innovative Industrial Properties on an Expansion Spree

Innovative Industrial Properties Inc (NYSE: IIPR), a Real Estate Company focussed on acquiring, developing, leasing and managing Cannabis facilities in the regulated market, announced the signing of two sale-leaseback agreements with subsidiaries of GR Companies Inc. (Grassroots) for approximately 105,000 square feet of industrial space,...

Savara Soars on Grant of Breakthrough Therapy Designation for Molgradex

Savara Inc (NASDAQ: SVRA), a Company focused on addressing the needs of orphan lung diseases, announced the grant of a breakthrough designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), indicated for the treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). The US...

WordPress Video Lightbox Plugin